Skip to content
Review

Latitude, Seasonality, and Circadian Determinants of Outcomes of Systemic Cancer Therapy: Evidence from Chemotherapy, Immunotherapy, and Chemo-Immunotherapy Combinations. A Systematic Review.

Aug 2026 · Critical reviews in oncology/hematology · Vol 226, pp. 105509 · 0 citations · 47 references
Medicine

TL;DR

Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes.

Abstract

Objectives

To evaluate whether treatment timing (chronotherapy/time-of-day infusion), seasonality, geographic latitude, and related vitamin D status are associated with efficacy and toxicity outcomes of systemic therapy for solid tumors. STUDY

Design

PRISMA 2020-guided systematic review with qualitative synthesis.

Methods

PubMed/MEDLINE, Embase, Web of Science, and Scopus were searched from inception to January 20, 2026, with additional screening of oncology conference proceedings and trial registries. Eligible studies included randomized trials, observational cohorts, and meta-analyses assessing treatment timing, season/latitude proxies (including serum 25-hydroxyvitamin D), and/or objective circadian disruption, with outcomes including overall survival (OS), progression-free survival (PFS), response, and treatment-related toxicity. Two reviewers independently screened and extracted data using a predefined form. Risk of bias was assessed using Cochrane RoB 2.0 and the Newcastle-Ottawa Scale. Because of substantial clinical and methodological heterogeneity, findings were synthesized qualitatively and stratified by exposure domain and study design.

Results

Thirty-five studies were included (6 randomized trials, 2 patient-level meta-analyses, 5 prospective cohorts, 22 retrospective cohorts). Chronomodulated chemotherapy consistently reduced toxicity and sometimes improved response/time-to-progression, but survival effects were heterogeneous and appeared sex-dependent. Earlier immune checkpoint inhibitor administration (morning/early daytime) was associated with longer OS/PFS in mostly retrospective cohorts; these findings should therefore be considered hypothesis-generating pending prospective confirmation. Seasonal and latitude analyses generally showed worse outcomes in winter and at higher latitudes, although ecological and observational designs limited causal inference. Higher vitamin D levels and supplementation during immunotherapy were associated with improved survival but may partly reflect baseline health status and other prognostic factors. Objective circadian disruption was repeatedly associated with poorer prognosis.

Conclusions

Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes. Evidence is strongest for chemotherapy chronomodulation in selected historical randomized trials, whereas immunotherapy timing, seasonal/latitude effects, and vitamin D associations remain less causally established. Prospective randomized studies should test pragmatic interventions such as structured ICI scheduling and vitamin D assessment/correction before routine implementation.

View source

Similar papers

Review Open access Sep 2026

Revisiting metformin as a chemotherapy adjuvant: a systematic review and meta-analysis based on recent randomized-controlled trials

Adjunctive metformin did not improve overall or PFS but was associated with a higher ORR, driven by increased complete responses, without increasing high-grade toxicity, without increasing high-grade toxicity.

Bushra Wadi Bin Saddiq, Ahmed Salah Morad, T. Khan et al. · 0 citations
Meta-analysis Open access Sep 2026

Overall survival with immune checkpoint inhibitors across treatment settings and clinical and PD-L1-defined subgroups in advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of randomized trials

Introduction To quantify overall-survival effects of immune-checkpoint-inhibitor (ICI)-containing regimens by treatment line and to evaluate whether clinical characteristics or PD-L1 definitions modify relative treatment benefit in advanced esophageal squamous cell carcinoma (ESCC). Methods PubMed, Embase, the Cochrane...

Bing Wang, Xiao-Yu Han, Zeng-Li Shen · 0 citations
Review Sep 2026

Biologic Therapies in Thyroid Eye Disease: A PRISMA-Based Systematic Review and Meta-Analysis of Clinical Outcomes, Safety Profiles and Impact on Surgical Management

Background: Biologic therapies have transformed Thyroid Eye Disease (TED) management, but their comparative efficacy, safety, durability and effects on subsequent rehabilitative surgery remain uncertain. Objective: To evaluate the efficacy and safety of teprotumumab, rituximab and tocilizumab across TED phenotypes and...

N. Yadav, Shimpa Kundan, Swati Singh et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Background Immune checkpoint inhibitors combined with chemotherapy have improved pathological responses in early-stage triple-negative breast cancer (TNBC), but the magnitude of benefit and associated toxicity remain variable across trials. This systematic review and meta-analysis aimed to evaluate the efficacy and saf...

Jia-Le Li, Pei-Tao Wu, Jing-Shu Song et al. · 0 citations
Review Open access Sep 2026

Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis

Pretreatment body mass index (BMI) has been associated with outcomes during immune checkpoint inhibitor (ICI) therapy, but study-specific categories and incomplete adjustment complicate interpretation. We evaluated associations with efficacy and toxicity across tumor types and BMI definitions. We searched...

Si-Yu Sun, Jun-Hao Zhang, Yan Li et al. · 0 citations
Review Open access Sep 2026

Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials

Background First-line chemoimmunotherapy has become a major therapeutic strategy for advanced gastric and gastroesophageal junction cancer, yet the magnitude of survival benefit, regional consistency, and toxicity trade-offs remain important considerations. We conducted an systematic review and meta-analysis of randomi...

Xiao Zeng, Jia-Xi Chen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.